Abstract | OBJECTIVE: METHODS: We report on a 37-year-old female patient who was given risperidone to treat an acute delusional disorder. Despite receiving a very low dose, the patient suffered from an intoxication. We inferred that an excessively raised plasma level of risperidone may result from a pharmacologically relevant disorder of metabolism. RESULTS: The molecular genetic investigation revealed a compound heterozygous mutation in the CYP2D6 gene and thus documented a genetic predisposition as a "poor [non]metabolizer". CONCLUSIONS: In intoxications with psychoactive agents, the presence of an enzyme defect in the P450 system should be considered as an additional possible cause.
|
Authors | Maria Strauss, Wolfram Heinritz, Ulrich Hegerl, Andrea Kopf |
Journal | Psychiatrische Praxis
(Psychiatr Prax)
Vol. 37
Issue 4
Pg. 199-201
(May 2010)
ISSN: 1439-0876 [Electronic] Germany |
Vernacular Title | Risperidonintoxikation bei genetischer Disposition als "poor [non]metabolizer". |
PMID | 20225176
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antipsychotic Agents
- Cyclohexanols
- Serotonin Uptake Inhibitors
- Venlafaxine Hydrochloride
- Cytochrome P-450 CYP2D6
- Risperidone
|
Topics |
- Adult
- Antipsychotic Agents
(pharmacokinetics, therapeutic use, toxicity)
- Chromosomes, Human, Pair 22
(genetics)
- Cyclohexanols
(pharmacokinetics, therapeutic use)
- Cytochrome P-450 CYP2D6
(genetics)
- DNA Mutational Analysis
- Delusions
(blood, drug therapy, genetics)
- Dose-Response Relationship, Drug
- Drug Monitoring
- Drug Therapy, Combination
- Exons
(genetics)
- Female
- Genetic Carrier Screening
- Humans
- Inactivation, Metabolic
(genetics)
- Introns
(genetics)
- Metabolic Clearance Rate
- Psychotic Disorders
(blood, drug therapy, genetics)
- Risperidone
(pharmacokinetics, therapeutic use, toxicity)
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
- Venlafaxine Hydrochloride
|